# EDGAR Filing Document

**Accession Number:** 0001348911
**File Stem:** 0001140361-26-025858
**Filing Date:** 2026-6
**Character Count:** 3292
**Document Hash:** 540735450a803597131ec2bc061ef46c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-025858.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001140361-26-025858

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260622

**DATE AS OF CHANGE**: 20260622

**EFFECTIVENESS DATE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KalVista Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001348911
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 200915291
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36830
- **FILM NUMBER:** 261105114

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702
- **BUSINESS PHONE:** (857) 999-0075

**MAIL ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20140916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery, Inc
- **DATE OF NAME CHANGE:** 20130102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery Inc
- **DATE OF NAME CHANGE:** 20060105

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

### FORM 15

#### <br>

#### CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

#### UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

#### OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934.

#### Commission File No. 001-36830

#### <br>

------

## KalVista Pharmaceuticals, Inc.

#### (Exact name of registrant as specified in its charter)

#### <br>

------

#### 200 Crossing Boulevard

#### Framingham, Massachusetts 01702
(857) 999-0075

#### (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### Common Stock, par value $0.001 per share

#### (Title of each class of securities covered by this Form)

#### None

#### (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

#### <br>

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports: <br>

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One holder.

------

Pursuant to the requirements of the Securities Exchange Act of 1934, KalVista Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **KalVista Pharmaceuticals, Inc.** | **KalVista Pharmaceuticals, Inc.** |
| Date: | June 22, 2026 | By: | /s/ John Hess |
|  |  | Name: | John Hess |
|  |  | Title: | Chairman of the Board; President; General Manager |

---

------